# US 2019/0317092 A1 · Fab-linked glycans as biomarker for the transition from a pre-disease "at-risk-phase" to rheumatoid arthritis; aav or sjögren syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0317092 A1
- Document ID: US20190317092A1
- Status: Published application
- Kind: A1
- Application number: 16/464,651
- Filed: 2017-11-24
- Published: 2019-10-17
- Earliest claimed: 2016-11-25
- Assignees: Academisch Ziekenhuis Leiden (H.O.D.N. Lumc)
- Applicants: Academisch Ziekenhuis Leiden h.o.d.n. LUMC
- Inventors: Thomas Willem Johannes Huizinga; Reinaldus Everardus Maria Toes; Leendert Adrianus Trouw; Hans Ulrich Scherer
- Web page: https://patentgrep.com/patent/US20190317092A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/102: Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
- G01N 2800/328: Vasculitis, i.e. inflammation of blood vessels
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Means and methods for determining whether an individual that does not have rheumatoid arthritis, AAV or Sjögren syndrome at the moment of sampling is at risk of developing the disease, the method comprising determining whether an antibody-containing sample of the individual comprises an autoantibody associated with the disease that comprises an N-linked glycosylation at one or more positions in a Fab-portion of the antibody, the method further comprising determining the risk of the individual for developing the disease. The disease is preferably rheumatoid arthritis.

## Claims

### Claim 1

A method of determining whether an individual that does not have rheumatoid arthritis, Sjögren syndrome or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) at the moment of sampling is at risk of developing said disease, the method comprising:
determining whether an antibody-containing sample of the individual comprises an autoantibody associated with said disease;
determining whether the antibody comprises an N-linked glycosylation at one or more positions in a Fab-portion of the antibody; and
determining the risk of the individual for developing said disease on the basis of said determinations.

### Claim 2

A method of analyzing an antibody-containing sample of an individual, the method comprising:
determining whether said sample comprises an autoantibody associated with rheumatoid arthritis, Sjögren syndrome or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) that comprises an N-linked glycosylation at one or more positions in a Fab-portion of the antibody, the method characterized in that the sample is a sample of an individual that does not have rheumatoid arthritis symptoms, Sjögren syndrome symptoms or AAV symptoms at the moment of sampling.

### Claim 3

A method of preventing or delaying the development of a rheumatoid arthritis symptom, a Sjögren syndrome symptom or an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) symptom in an individual, the method comprising:
determining whether a sample of the individual contains an autoantibody associated with said disease;
determining whether the antibody has an N-linked glycosylated Fab-portion;
wherein the sample is an antibody-containing sample of the individual and the individual did not have rheumatoid arthritis, Sjögren syndrome and AAV at the time of sampling; and
treating the individual with a medicament for said disease prior to or at the onset of the individual presenting with said disease.

### Claim 4

A method of monitoring an individual at risk of developing rheumatoid arthritis, Sjögren syndrome or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), the method comprising monitoring the presence and/or the onset of an autoantibody associated with said disease in periodic antibody-containing samples of an individual, wherein the method further comprises determining whether a detected autoantibody associated with said disease comprises an N-linked glycan at one or more positions in a Fab-portion of the antibody.

### Claim 5

A method of treating an individual at risk of developing one or more of rheumatoid arthritis, Sjögren syndrome or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), wherein the individual is determined to be at risk by the detection of an autoantibody associated with said disease, which autoantibody comprises N-linked glycosylation at one or more positions in a Fab-portion of the antibody in an antibody-containing sample of the individual.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the individual is treated prior to or at the onset of the individual presenting with arthritis symptoms.

### Claim 7

A method of purifying antibodies for the measurement of antibodies comprising N-linked glycan on a Fab-portion thereof, the method comprising:
contacting an antibody sample with a solid surface that comprises a peptide or protein that comprises a modified protein epitope;
removing unbound antibody and eluting bound antibody from said solid surface;
incubating eluted antibody with a solid surface comprising a molecule that can bind an N-linked glycan on a Fab-portion of an antibody;
removing unbound molecules; and
determining whether an antibody has bound to said solid surface,
wherein a bound antibody indicates the presence of an N-linked glycan on a Fab-portion of an antibody in said sample.

### Claim 8

A method of purifying antibodies for the measurement of antibodies that have an N-linked glycan on a Fab-portion, the method comprising:
contacting an antibody sample with a solid surface that comprises a peptide or protein that comprises a modified protein epitope;
removing unbound antibody;
incubating said solid surface with a molecule that can bind an N-linked glycan on a Fab-portion of an antibody;
removing unbound molecules; and
determining whether a molecule has bound to said solid surface,
wherein a bound molecule indicates the presence of an N-linked glycan on a Fab-portion of an antibody in said sample.

### Claim 9

A method of purifying antibodies for the measurement of antibodies that have an N-linked glycan on a Fab-portion, the method comprising:
contacting an antibody sample with a solid surface that comprises a peptide or protein that comprises a modified protein epitope;
removing unbound antibody;
incubating bound antibody with an enzyme that separates glycan from said antibody;
collecting glycans; and
determining whether the collected glycans comprise a Fab-portion-specific glycan;
wherein the sample is an antibody sample of an individual at risk of developing rheumatoid arthritis, Sjögren syndrome or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

### Claim 10

A method of purifying antibodies with N-linked glycosylation on a Fab-portion of the antibody, the method comprising:
incubating an antibody sample with a solid surface that comprises a molecule that can bind an N-linked glycan on a Fab-portion of an antibody;
washing said solid surface and collecting bound antibody;
incubating collected antibody with a peptide or protein that comprises a modified protein epitope, removing unbound antibody; and
determining whether said peptide or protein had bound antibody.

### Claim 11 (depends on 10)

The method of claim 10, wherein said sample comprises purified antibodies.

### Claim 12

A method comprising:
contacting an antibody sample with a solid surface that comprises a peptide or protein that comprises a modified protein epitope;
removing unbound antibody;
incubating said solid surface with a molecule that can bind an N-linked glycan on a Fab-portion of an antibody;
removing unbound molecules; and
determining whether a molecule has bound to said solid surface.

### Claim 13 (depends on 1)

The method of claim 1, wherein the sample is an antibody sample of an individual at risk of developing rheumatoid arthritis, Sjögren syndrome or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

### Claim 14 (depends on 1)

The method of claim 1, wherein the sample is an antibody sample of an individual of which an earlier antibody sample was tested positive for an autoantibody.

### Claim 15 (depends on 14)

The method of claim 14, wherein 10% or less of the autoantibody of said earlier antibody sample comprises an N-linked glycan on a Fab-portion thereof.

### Claim 16 (depends on 14)

The method of claim 14, wherein said autoantibody is an anti-modified protein antibody (AMPA).

### Claim 17 (depends on 1)

The method of claim 1, wherein the antibodies are cleaved to produce Fab and Fc fragments.

### Claim 18

A method of determining whether an antibody sample comprises an anti-modified protein antibody (AMPA), a citrulline, a homo-citrulline and/or an acetylated lysine-binding AMPA, the method comprising:
contacting antibodies of the sample with a peptide or protein that comprises a modified protein epitope, a citrulline, homo-citrulline, or acetylated lysine;
contacting antibodies of the sample with a molecule that can bind an N-linked glycan on a Fab-portion of an antibody; and
determining whether an antibody with a N-linked glycan on a Fab-portion of the antibody has bound to the modified protein epitope in the peptide or protein, wherein the modified protein epitope comprises citrulline, a homo-citrulline or an acetylated lysine.

### Claim 19 (depends on 18)

The method of claim 18, wherein the sample is a sample of an individual that does not have rheumatoid arthritis at the moment of sampling.

### Claim 20 (depends on 18)

The method of claim 18, wherein an AMPA, preferably a citrullinated protein antigens antibody (ACPA), lysine acetylated protein antigens antibody (AAPA) and/or anti-CarP antibody had been detected in a similar earlier sample of the individual.

### Claim 21 (depends on 20)

The method of claim 20, wherein the AMPA in the earlier sample tested negative for the presence of N-linked glycosylation on a Fab-portion of the antibodies.

### Claim 22 (depends on 18)

The method of claim 18, wherein the individual is at risk of developing arthritis.

### Claim 23 (depends on 18)

The method of claim 18, wherein the glycan-binding molecule comprises a lectin, a sialic acid residue binding lectin, a member of the SIGLEC family, CD22 or the sialic acid binding part of said lectin.

### Claim 24 (depends on 23)

The method of claim 23, wherein the lectin can simultaneously bind two sialic acid residues.

### Claim 25

A kit of parts useful in the detection of an autoantibody associated with rheumatoid arthritis, Sjögren syndrome or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in a sample, the kit comprising a peptide or protein that can bind said autoantibody and a molecule that can bind an N-linked glycan on a Fab-portion of an antibody.

### Claim 26 (depends on 25)

A kit of parts according to claim 25, wherein the peptide; protein or the molecule that can bind an N-linked glycan is linked to a solid surface.

### Claim 27

A method of determining whether an individual has an autoantibody associated with rheumatoid arthritis, Sjögren syndrome or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with an N-linked glycan on a Fab-portion of the antibody, the method comprising:
contacting a B-cell-containing sample of the individual with a peptide or protein that can bind said autoantibody;
separating B-cells bound to said peptide or protein from unbound B-cells;
sequencing nucleic acid encoding at least the CDR1 of the heavy chain variable region and/or the CDR1 of the light chain variable region of a B-cell receptor of said bound B-cells; and
determining whether the nucleic acid sequence codes for an N-linked glycosylation consensus amino acid sequence.

### Claim 28 (depends on 27)

The method of claim 27, comprising sequencing at least the CDRs of the heavy chain variable region and/or the CDRs of the light chain variable region.
